MiMedx Net Income From Continuing Ops from 2010 to 2026
| MDXG Stock | USD 5.12 0.03 0.59% |
Net Income From Continuing Ops | First Reported 2011-03-31 | Previous Quarter 9.6 M | Current Value 16.7 M | Quarterly Volatility 11.8 M |
Check MiMedx financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MiMedx's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.7 M, Interest Expense of 1.8 M or Selling General Administrative of 130 M, as well as many indicators such as Price To Sales Ratio of 4.43, Dividend Yield of 0.0 or PTB Ratio of 8.0. MiMedx financial statements analysis is a perfect complement when working with MiMedx Valuation or Volatility modules.
MiMedx | Net Income From Continuing Ops | Build AI portfolio with MiMedx Stock |
The Net Income From Continuing Ops trend for MiMedx Group offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether MiMedx is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest MiMedx's Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of MiMedx Group over the last few years. It is MiMedx's Net Income From Continuing Ops historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MiMedx's overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
MiMedx Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | 3,453,006 | |
| Coefficient Of Variation | 889.84 | |
| Mean Deviation | 24,536,972 | |
| Median | (4,111,853) | |
| Standard Deviation | 30,726,207 | |
| Sample Variance | 944.1T | |
| Range | 114M | |
| R-Value | 0.24 | |
| Mean Square Error | 948.7T | |
| R-Squared | 0.06 | |
| Significance | 0.35 | |
| Slope | 1,464,521 | |
| Total Sum of Squares | 15105.6T |
MiMedx Net Income From Continuing Ops History
About MiMedx Financial Statements
MiMedx stakeholders use historical fundamental indicators, such as MiMedx's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although MiMedx investors may analyze each financial statement separately, they are all interrelated. For example, changes in MiMedx's assets and liabilities are reflected in the revenues and expenses on MiMedx's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in MiMedx Group. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 37.8 M | 39.7 M |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of MiMedx Correlation against competitors. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Can Biotechnology industry sustain growth momentum? Does MiMedx have expansion opportunities? Factors like these will boost the valuation of MiMedx. Expected growth trajectory for MiMedx significantly influences the price investors are willing to assign. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating MiMedx demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Quarterly Earnings Growth 1.138 | Earnings Share 0.27 | Revenue Per Share | Quarterly Revenue Growth 0.353 | Return On Assets |
The market value of MiMedx Group is measured differently than its book value, which is the value of MiMedx that is recorded on the company's balance sheet. Investors also form their own opinion of MiMedx's value that differs from its market value or its book value, called intrinsic value, which is MiMedx's true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because MiMedx's market value can be influenced by many factors that don't directly affect MiMedx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that MiMedx's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether MiMedx represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, MiMedx's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.